The initial clinical experience of using Ovosorb antiprotease hemosorbent in the combined treatment of dermatoses

: The new antiprotease hemosorbent Ovosorb was tested during the performance of blood perfusion (BP) used as part of multimodality treatment of 11 patients. Of these, 2 presented with disseminated psoriasis, 3 with arthropathic psoriasis, 1 with psoriatic erythrodermia, 4 with atopic dermatitis, and 1 with recurrent urticaria. BP with the use of the hemosorbent Ovosorb produced the highest effect in patients with atopic dermatitis, psoriatic erythrodermia and recurrent urticaria; BP with Ovosorb was less effective in disseminated psoriasis. The clinical effect was lacking in patients with arthropathic psoriasis. Ovosorb possesses remarkable detoxifying properties, good blood compatibility; it does not provoke any complications in patients with different forms of psoriasis, atopic dermatitis, and urticaria.